#United States #SkinCure Oncology #Image-Guided SRT #Burr Ridge #Mohs Surgery

SkinCure Oncology Files a Lawsuit Against ACMS

SkinCure Oncology, a prominent leader in nonmelanoma skin cancer treatment, has made headlines by filing a lawsuit against the American College of Mohs Surgery (ACMS). The suit, submitted on March 27, 2026, stems from allegations of trade libel, defamation, and violations of the federal Lanham Act. The company’s aim is to safeguard its reputation as a provider of Image-Guided Superficial Radiation Therapy (Image-Guided SRT), which is marketed to patients through the GentleCure ExperienceSM initiative.

Background of the Dispute

SkinCure Oncology represents a significant force in the fight against nonmelanoma skin cancer, offering an advanced nonsurgical treatment that has been embraced by numerous dermatologists and Mohs surgeons across the nation. Partnering with over 500 medical professionals, SkinCure has successfully treated more than 140,000 patients using its proprietary Image-Guided SRT. This legal action suggests escalating tensions between SkinCure and the ACMS, relating to concerns over public perception and trust in dermatological practices.

The Claims

The lawsuit claims that the actions and statements from the ACMS have led to harmful misrepresentations regarding SkinCure's practices and treatment methodologies. Defamation and trade libel are serious accusations that could have far-reaching implications for both organizations.

According to SkinCure, such actions not only undermine their substantial achievements in patient care but also jeopardize patients' access to innovative treatment options that could significantly improve their quality of life. The organization emphasizes that their Image-Guided SRT offers a safe and effective alternative for patients, positioning themselves as champions for those living with skin cancer.

Implications for Patients and Practice

As legal disputes unfold, one of the primary concerns remains the potential impact on patient care. The treatment options available to patients could be influenced by the information that circulates in professional circles and public platforms. SkinCure aims to continue providing its cutting-edge treatment while ensuring that patients are informed about all available options in a transparent manner.

The GentleCure ExperienceSM has been pivotal in educating and helping patients understand how Image-Guided SRT works, and why it’s a suitable option for nonmelanoma skin cancers. Thus, the lawsuit's outcome could significantly affect how treatments are perceived and utilized by practitioners and patients alike.

Moving Forward

The legal proceedings may put a spotlight on the intricacies of the medical field concerning trade practices and standards of care. As both parties prepare for what may be an extensive legal battle, the focus remains on healthy competition and the importance of patient safety and education. SkinCure’s commitment to its mission suggests that they will stand firm against allegations, focusing on achieving the best outcomes for their patients.

In the end, the suit not only represents a fight for legal and professional integrity but also for the well-being of patients who depend on innovative treatments. Stakeholders from various sectors, including medical professionals, insurers, and patients, will be closely monitoring this unfolding legal saga.

For further insights and updates on this matter, you can visit SkinCure Oncology’s official website or follow their progress in the legal realm as they continue to advocate for what they believe is right for the skin cancer community.